The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Subscribe To Our Newsletter & Stay Updated
